Business Context and Reporting Period
Company: IDEAYA Biosciences, Inc. (IDYA)
Filing Type: Form 8-K (Current Report)
Date of Report: March 10, 2023
Event: Item 8.01 Other Events regarding the closure of Silicon Valley Bank (SVB) by the FDIC.
Key Financial Metrics
This filing does not report standard financial performance metrics such as revenue, profit, or cash flow for a specific period. The only financial data disclosed relates to potential exposure to the SVB receivership:
- Potential Exposure at SVB: Maximum of mid-single digit millions of dollars in cash, cash equivalents, or marketable securities.
- Total Liquidity Status: Substantially all of the Company's cash, cash equivalents, and marketable securities are held in separate accounts at custodian banks and/or other banks, not directly exposed to SVB consequences.
Material Changes
The filing addresses the external event of the FDIC appointing itself as receiver for SVB. The Company states there will be no material impact to its operations or cash runway guidance as a result of this action.
Guidance, Outlook, and Risks
Management Commentary: The Company believes the SVB closure will not materially impact operations or cash runway guidance.
Risks and Contingencies: The report includes standard forward-looking statement disclaimers. It notes that actual results could differ significantly due to risks related to preclinical and clinical development programs and general business risks. Investors are directed to the Annual Report on Form 10-K filed on March 7, 2023, for a detailed description of risks.
Key Facts for Investor Verification
- Verify the exact amount of funds held at SVB against the "mid-single digit millions" disclosure.
- Confirm the status of the Company's cash runway guidance in subsequent filings or press releases.
- Review the March 7, 2023 Form 10-K for comprehensive risk factors and detailed financial position.
- Monitor for any updates regarding the recovery of funds from the FDIC receivership process.